Neurocrine Biosciences Inc (NBIX)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 233,000 | 251,100 | 262,900 | 340,800 | 187,100 |
| Short-term investments | US$ in thousands | 843,100 | 780,500 | 726,400 | 370,500 | 613,900 |
| Receivables | US$ in thousands | 493,500 | 439,300 | 350,000 | 187,700 | 160,800 |
| Total current liabilities | US$ in thousands | 507,700 | 654,800 | 537,700 | 245,800 | 186,500 |
| Quick ratio | 3.09 | 2.25 | 2.49 | 3.66 | 5.16 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($233,000K
+ $843,100K
+ $493,500K)
÷ $507,700K
= 3.09
The quick ratio of Neurocrine Biosciences Inc has shown a decreasing trend over the years, declining from 5.16 as of December 31, 2020, to 3.66 as of December 31, 2021, further dropping to 2.49 as of December 31, 2022. This indicates a potential decrease in the company's ability to meet its short-term liabilities with its most liquid assets. However, there was a slight improvement to 3.09 as of December 31, 2024, suggesting a better liquidity position compared to the previous year. Overall, the company may need to closely monitor its liquidity management to ensure it can meet its short-term obligations efficiently.
Peer comparison
Dec 31, 2024